EUVIMEDEUVIMED entdecken
Open Access

An efficient and robust strategy for developing cell lines through targeted integration

Duncan McVey iD, Charu Garg, Chaojie Wang, Aashir Awan, Rui Zheng, Jennifer Zhang, Steve Sturner, Erik Langsdorf, Le Yu, Krishnamurthy Shankarling, Giovanni Rizzi, Kitty Agarwal und 2 weitere

Biotechnology Progress · 2026-07 · 42 (4)

DOI: 10.1002/btpr.88509 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Progress, online erschienen am 02.04.2026. Verfasst von Duncan McVey und 13 weiteren Autor:innen. Beteiligte Einrichtung: Biologics Development, Bristol Myers Squibb, New Brunswick, New Jersey, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Cell Line. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reducing the time needed and enhancing predictability of outcomes for cell line development is an ongoing focus of improvement. Targeted integration (TI) where the expression cassettes for a biologic are inserted at a predefined locus, a landing pad, is one of the strategies that is used for this purpose. To be commercially viable the landing pad host cell must support high titers and the transgenes in the landing pad must be highly transcribed. To make such a host TI cell line takes a great deal of time and effort with little guarantee of success. Here we describe a strategy where we converted a stable high‐expressing mAb cell line and generated multiple TI host cell lines that are commercially relevant. We routinely generate 6 g/L mAb clones using our platform fit process and 8 to >10 g/L with process optimization that are phenotypically and genetically stable. We also created a duo‐landing pad where both landing pads reside in the same locus. This gives the opportunity to simplify the construction of differentially expressed genes since both landing pads are expected to perform equally.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalCell LineAnimalsHumansTransgenes

Substanzen

Antibodies, Monoclonal

Autor:innen und Institutionen

  • Biologics Development, Bristol Myers Squibb, New Brunswick, New Jersey, USA.

ORCID-Profile: Duncan McVey, Anurag Khetan

Zitieren

APA

McVey, D., Garg, C., Wang, C., Awan, A., Zheng, R., Zhang, J., Sturner, S., Langsdorf, E., Yu, L., Shankarling, K., Rizzi, G., Agarwal, K., Tremml, G., & Khetan, A. (2026). An efficient and robust strategy for developing cell lines through targeted integration. Biotechnology Progress, 42(4). https://doi.org/10.1002/btpr.88509

Vancouver

McVey D, Garg C, Wang C, Awan A, Zheng R, Zhang J, et al. An efficient and robust strategy for developing cell lines through targeted integration. Biotechnology Progress. 2026;42(4). doi:10.1002/btpr.88509

BibTeX
@article{McVey2026,
  author = {McVey, Duncan and Garg, Charu and Wang, Chaojie and Awan, Aashir and Zheng, Rui and Zhang, Jennifer and Sturner, Steve and Langsdorf, Erik and Yu, Le and Shankarling, Krishnamurthy and Rizzi, Giovanni and Agarwal, Kitty and Tremml, Gabi and Khetan, Anurag},
  title = {An efficient and robust strategy for developing cell lines through targeted integration},
  journal = {Biotechnology Progress},
  year = {2026},
  volume = {42},
  number = {4},
  doi = {10.1002/btpr.88509}
}
Kostenlos starten →